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https://doi.org/10.1016/j.cub.2020.12.018SUMMARYMismatch repair (MMR) safeguards genome stability through recognition and excision of DNA replication er-
rors.1–4 How eukaryotic MMR targets the newly replicated strand in vivo has not been established. MMR re-
actions reconstituted in vitro are directed to the strand containing a preexisting nick or gap,5–8 suggesting
that strand discontinuities could act as discrimination signals. Another candidate is the proliferating cell nu-
clear antigen (PCNA) that is loaded at replication forks and is required for the activation of Mlh1-Pms1
endonuclease.7–9 Here, we discovered that overexpression of DNA ligase I (Cdc9) in Saccharomyces cerevi-
siae causes elevatedmutation rates and increased chromatin-bound PCNA levels and accumulation of Pms1
foci that areMMR intermediates, suggesting that premature ligation of replication-associated nicks interferes
with MMR. We showed that yeast Pms1 expression is mainly restricted to S phase, in agreement with the
temporal coupling between MMR and DNA replication.10 Restricting Pms1 expression to the G2/M phase
caused a mutator phenotype that was exacerbated in the absence of the exonuclease Exo1. This mutator
phenotype was largely suppressed by increasing the lifetime of replication-associated DNA nicks, either
by reducing or delaying Cdc9 ligase activity in vivo. Therefore, Cdc9 dictates awindowof time forMMRdeter-
mined by transient DNA nicks that direct the Mlh1-Pms1 in a strand-specific manner. Because DNA nicks
occur on both newly synthesized leading and lagging strands,11 these results establish a general mechanism
for targetingMMR to the newly synthesizedDNA, thus preventing the accumulation ofmutations that underlie
the development of human cancer.RESULTS AND DISCUSSION
DNA mismatch repair (MMR) utilizes an excision-resynthesis
mechanism to correct mispaired bases that occur in DNA due
to errors during DNA synthesis.1–4 To repair these errors, MMR
must target only the newly synthesized daughter strand; howev-
er, it remains unclear how this machinery discriminates between
the parental strand and the daughter strand in eukaryotic living
cells. It is known that eukaryotic MMR is temporally coupled to
DNA replication, as newly replicated DNA in S. cerevisiae is pro-
ficient for MMR for no longer than 10 min during S phase.10 This
result suggests that the MMR strand-discrimination signal in eu-
karyotes involves some aspect of the DNA replication machinery
and/or an S-phase-associated property of the daughter strand
itself.1268 Current Biology 31, 1268–1276, March 22, 2021 ª 2020 The Au
This is an open access article under the CC BY-NC-ND license (http://Several studies in eukaryotes have investigated transient fea-
tures of the newly replicated DNA as candidate strand-discrimi-
nation signals. Single-strand discontinuities (nicks) present
between Okazaki fragments or those generated upon removal
of misincorporated ribonucleotides have been proposed to
serve as strand-discrimination signals.12,13 However, the inacti-
vation of the ribonucleotide excision repair (RER) pathway
causes far lower mutation rates than complete loss of MMR
and results in an unusual spectrum of mutations whose forma-
tion depends on the activity of topoisomerase I.14 In contrast,
mutations affecting MMR strand-discrimination components in
Escherichia coli, including the Dammethylase or theMutH endo-
nuclease, result in complete loss of MMR function.15 Another
candidate is Proliferating Cell Nuclear Antigen (PCNA), which is
loaded asymmetrically at the replication fork,16 interacts withthor(s). Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Mlh1-Pms1 (called MLH1-PMS2 in human).7–9,18,19 PCNA has
been proposed to act as a strand-discrimination signal even in
the absence of daughter strand discontinuities.20 However, this
mechanism is not consistent with the very modest increase in
mutation rate caused by loss of the Msh6-PCNA interaction
that would be required to target Msh2-Msh6 to newly replicated
DNA or retain PCNA at themispair site.17 Furthermore, the ability
of new PCNA trimers to be loaded at nicks in DNA raises the
question of whether replication-associated PCNA or replica-
tion-associated nicks are ultimately the strand discrimination
signal.
If DNA nicks areMMR strand-discrimination signals in vivo, we
reasoned that overexpression of the replicative DNA ligase Cdc9
in S. cerevisiae should reduce nick lifetime in newly replicated
DNA and potentially cause a mutator phenotype. To increase
the expression of Cdc9, we constructed high-copy-number vec-
tors expressing wild-type (WT) CDC9, two CDC9 ligase-defec-
tive mutants (cdc9-K419A and cdc9-K598A),21,22 and a Cdc9
variant that does not interact with PCNA in vitro (cdc9-FFAA).23
Next, we examined whether these plasmids could support the
growth of a yeast strain in which the endogenous Cdc9 protein
was depleted using the auxin-inducible degron (AID) system.24
For this, we generated a yeast strain with a chromosomally en-
coded version of CDC9 fused to the AID-tag (CDC9-AID), which,
in the presence of the plant hormone auxin and the auxin-recep-
tor Afb2, triggers the ubiquitin-mediated proteasomal degrada-
tion of the protein fused to the AID-tag. In agreement with previ-
ous results,25 WT-CDC9 and the cdc9-FFAA mutant promoted
survival of the CDC9-AID strain on auxin-containing medium,
whereas the ligase-defective mutants did not (Figure S1A),
despite similar levels of expression (Figure S1B). WT Cdc9 over-
expression driven by this high-copy-number plasmid caused a
modest increase in mutation rates in a WT strain and a strong
mutator phenotype in an exo1D strain (Figure 1A; Table S1),
which lacks the Exo1-dependent MMR pathway.26,27 This in-
crease in the mutation rates was also observed, to a lesser
extent, with the cdc9-FFAA allele but was not seen with ligase-
defective mutants, indicating that this mutagenic effect requires
the overexpression of ligase-proficient Cdc9 and is promoted by
an intact PCNA interaction motif. These requirements differ from
the trinucleotide repeat (TNR) instability phenotype caused by
Cdc9 overexpression, which depends on PCNA recruitment
but not on ligase activity and was attributed to a competition be-
tween Cdc9 and the flap endonuclease Rad27 for PCNA
binding.22
Mispair recognition by Msh2-Msh6 or Msh2-Msh3 promotes
recruitment of the Mlh1-Pms1 endonuclease. Recruitment can
be observed as discrete foci in yeast strains expressing a
Pms1-4GFP fusion; these Pms1 foci are MMR intermediates
that accumulate when downstreamMMR functions are compro-
mised (due to mutations affecting Exo1 or preventing the activa-
tion of the Mlh1-Pms1 endonuclease) or due to increased levels
of mispaired bases.19,28,29 Overexpression of WT-CDC9 or
cdc9-FFAA in an exo1D strain caused an increase in the percent-
age of Pms1 foci-containing cells with P2 foci per cell (Figures
1B and 1C). In contrast, overexpression of ligase-defective
cdc9 variants modestly reduced Pms1 foci levels. These results
suggest that overexpression of functional Cdc9 either slowsdownstream steps in MMR or inhibits MMR at a step prior to
Mlh1-Pms1 turnover.
In agreement with the Cdc9-overexpression plasmid-based
results, we found that strains in which we replaced the endoge-
nous CDC9 promoter with the strong constitutive promoter
pGPD (CDC9-OE) (causing a 50-fold increase in Cdc9 levels;
Figure S1C) showed a modest mutator phenotype that was
greatly exacerbated by mutations that prevent Exo1-dependent
MMR (an EXO1 deletion or an exo1-FFAA-D571-702 mutant
allele, which cannot be recruited by Msh2 or Mlh1 to MMR
sites30) (Figure 2A; Table S2). To determine whether MMR de-
fects induced byCDC9-OEwere only seen in the presence of de-
fects in Exo1-dependent MMR, we combined the CDC9-OE
allele with mutations that disrupt the Exo1-independent MMR
pathway: pol30-K217E, which prevents PCNA-dependent acti-
vation of the Mlh1-Pms1 endonuclease19 and pms1-A99V (pre-
viously called pms1-A130V), which affects a residue in the
Pms1 ATPase domain and reduces endonuclease activation.26
We found that CDC9-OE caused a synergistic increase in muta-
tion rates in combination with both the pol30-K217E and pms1-
A99V mutations, indicating that Cdc9 overexpression affects
both Exo1-dependent and Exo1-independent MMR pathways
(Figure 2A). Consistent with this, the CDC9-OE exo1D pol30-
K217E triple mutant had mutation rates that were significantly
higher than those of the exo1D pol30-K217E, CDC9-OE exo1D
and CDC9-OE pol30-K217E double mutants. Even though the
CDC9-OE allele in combination with an msh2D mutation did
not cause a synergistic increase in frameshift mutation rates (Fig-
ure 2A), theCDC9-OE exo1D pol30-K217E triple mutant showed
mutation rates that were modestly higher than that of the MMR-
deficient msh2D strain (Figure 2A; Table S2). This result raises
the possibility that some interaction between Cdc9 overexpres-
sion, the absence of Exo1, and disruption of the positively
charged surface at the PCNA-DNA interaction surface caused
by the pol30-K217E mutation leads to an increased accumula-
tion ofmispairs that does not occur when Cdc9 is overexpressed
in the absence of MMR.
We hypothesized that the impaired MMR function caused by
CDC9-OE could be the result of the premature ligation of DNA
replication-associated nicks. Leading-strand nicks have been
suggested to be due to the processing of misincorporated ribo-
nucleotides, as Polε, the leading-strand DNA polymerase, incor-
porates ribonucleotides four timesmore frequently than Pold, the
lagging-strand DNA polymerase.31 If ribonucleotide excision
plays an important role in MMR strand discrimination, then
combining the CDC9-OE allele with a deletion of the RNH201
gene, which encodes the catalytic subunit of RNase H2, should
cause increasedmutation rates. In contrast, we found that muta-
tion rates in the double-mutant strain CDC9-OE rnh201D were
similar to that of the CDC9-OE strain; and the CDC9-OE exo1D
rnh201D triple mutant was no more MMR defective than the
CDC9-OE exo1D strain (Figure 2B; Table S2). These results sug-
gest that RER-associated strand discontinuities are not a major
source of MMR strand-discrimination signals.
To further characterize the mutator phenotype associated with
Cdc9 overexpression, we analyzed CAN1 mutational spectra.
The CAN1 mutation spectrum of the CDC9-OE single mutant
showed a similar frequency of base substitutions, a reduced fre-




Figure 1. Increased Cdc9 activity results in elevated mutation rates and accumulation of Pms1 foci
(A) Mutation rate analysis using the lys2-10A frameshift reversion assay in WT or exo1D strains carrying plasmids (2m) bearing WT-CDC9, the PCNA interaction-
deficient cdc9-FFAAmutant, the ligase-defective mutants cdc9-K491A and cdc9-K598A, or an empty vector (ev). Bars correspond to the median rate, with error
bars corresponding to the 95%confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to theWT strain. See also Figure S1
and Table S1.
(B) Percentage of cells containing Pms1-4GFP foci in exo1D strains transformed with plasmids shown in (A). Bars represent the average of the percentage of
nuclei containing foci; error bars represent standard error of the mean (SEM).
(C) Representative fluorescentmicroscopy live-cell images of cells containing Pms1 foci used for quantification shown in (B). Brightfield images are shown on top.
Scale bar represents 5 mm. p values indicated in (A) and (B) were calculated with the Mann-Whitney rank-sum test using SigmaPlot. *p% 0.05; **p% 0.01; ***p%
0.001; n.s., not significant.
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OPEN ACCESS Reportmutations as the WT strain (Table S3). These complex mutations
consisted of duplications or deletions (ranging from 15 to 72 bp)
flanked by direct repeats (Table S4) that strongly resemble the
mutations that arise in a rad27D mutant.32 This observation,
together with the TNR-instability phenotype reported for the
CDC9-OE strain,22 supports the idea that CDC9-OE interferes
with Rad27-dependent Okazaki fragment maturation, resulting
in large deletions and duplications that are not restricted to
DNA sequences containing TNRs. Consistent with this hypothe-
sis, combining the CDC9-OE allele with an msh2D mutation did
not cause a synergistic increase in mutation rates using MMR-
specific mutation rate assays (lys2-10A and hom3-10 frameshift
reversion assays), but it did cause elevated rates in the CAN1
inactivation assay, which detects a broader spectrum of1270 Current Biology 31, 1268–1276, March 22, 2021mutations than just those caused by MMR defects (Figure 2A;
Table S2). In contrast, the CAN1 mutational spectrum of the
exo1-FFAA-D571-702 single mutant was indistinguishable from
that of the WT strain (Table S3). Remarkably, the mutation spec-
trum of the CDC9-OE exo1-FFAA-D571-702 double mutant was
dominated by single-base frameshift mutations, primarily in the
three longest mononucleotide runs within the CAN1 gene (six
consecutive A or T bases). This spectrum is very similar to that
of the msh2D strain33 and is characteristic of MMR-deficient
strains. The difference between the CAN1 mutational spectra of
the CDC9-OE single-mutant and the CDC9-OE exo1-FFAA-
D571-702 double-mutant strains suggests that the elevated
CAN1 mutation rate in the double mutant is caused by an
increased MMR defect and not an increased defect in
A
B
Figure 2. Cdc9 overexpression interferes with both Exo1-dependent
and Exo1-independent MMR pathways
(A and B) Mutation rate analysis using the lys2-10A frameshift reversion re-
porter in the indicated yeast genetic backgrounds. Bars correspond to the
median rate, with error bars representing the 95% confidence interval.
Numbers on top of the bars indicate fold increase in mutation rate relative to
WT. p values were calculated with the Mann-Whitney rank-sum test using
SigmaPlot. ***p % 0.001; n.s., not significant. See also Table S2 for additional
mutation rate analysis using two alternative mutational reporters.
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OPEN ACCESSReportRad27-dependent Okazaki fragmentmaturation that would result
in the accumulation of large insertion and deletion mutations.
We considered the possibility that the MMR defects in Cdc9-
overexpressing strains could be caused by reduced levels of
PCNA impairing the activation of the Mlh1-Pms1 endonuclease,
as PCNA unloading by the Replication factor C-like complex
(RLC)-Elg1 depends on Okazaki fragment ligation.25 We there-
fore analyzed the effect of a CDC9-OE allele on chromatin-
bound PCNA levels (Figures 3A and S1D). As a control, we
included strains carrying the pol30-C81R allele or an elg1D mu-
tation, which cause reduced or increased levels of chromatin-
bound PCNA, respectively.34,35We found thatCDC9-OE causedan increased level of chromatin-bound PCNA (2-fold higher than
WT), suggesting that the mutator phenotype and the accumula-
tion of Pms1 foci in CDC9-OE strains are not a consequence of
reduced chromatin-bound PCNA. This increased chromatin-
bound PCNA is consistent with the results of previous experi-
ments in vitro showing that excesses of PCNA-interacting
proteins (e.g., Pold, FEN1, and DNA ligase I) prevent the RLC-
Elg1-dependent unloading of PCNA from DNA, most likely by
occluding access to the RLC-Elg1-unloader complex.36 Deletion
of ELG1 resulted in the accumulation of PCNA and SUMOylated
PCNA (indicated by high-molecular-weight bands recognized by
the PCNA-specific antibody) on chromatin (Figure S1D), in
accordance with a previous report.35 Similar accumulation of
chromatin-bound PCNA was observed in the CDC9-OE elg1D
double-mutant strain (Figure 3A). In contrast, chromatin-bound
PCNA levels were reduced by overexpression of ELG1 (ELG1-
OE) in both WT and CDC9-OE strains. Furthermore, ELG1-OE
caused a synergistic increase in mutation rate in the CDC9-OE
exo1D double mutant, resulting in mutation rates comparable
to that of anmsh2D single mutant, but only caused a small effect
when combined with an exo1Dmutation (Figure 3B; Table S2). In
addition, ELG1-OE resulted in increased levels of Pms1 foci by
itself and in combination with either exo1D or CDC9-OE alleles
(Figure 3C). Together, these results suggest that ELG1-OE-
driven loss of chromatin-bound PCNA interferes with MMR by
a different mechanism than CDC9-OE. Interestingly, mutations
resulting in a reduction in chromatin-bound PCNA do not strictly
correlate with increasedmutation rates (e.g., the ELG1-OE allele,
which causes reduced chromatin-bound PCNA levels, causes a
mild mutator phenotype, even in combination with an exo1Dmu-
tation) (Figures 3A and 3B; Table S2). Furthermore, it suggests
that the subpopulation of PCNA localized at mispair sites—
which activates the Mlh1-Pms1 endonuclease—is present at
levels that do not directly correlate with the total amount of chro-
matin-bound PCNA. Deletion of ELG1 (elg1D) causes a mild mu-
tator phenotype, even in combination with an exo1Dmutation or
with theCDC9-OE allele, and suppresses themutator phenotype
of a CDC9-OE exo1D strain in the lys2-10A assay (Figure 3D;
Table S2). This observation suggests that increased chro-
matin-bound PCNA levels can partially compensate for the ef-
fects caused by CDC9-OE and/or EXO1 deletion.
We have previously restricted the availability of the Msh2-
Msh6 mispair recognition complex to the G2/M phase in living
cells by fusing the MSH6 gene to the ‘‘G2/M-tag’’ (derived
from the cyclin CLB2 promoter and the Clb2 destruction box;
residues 1–181).10 Yeast strains expressing the G2/M-Msh6
fusion protein (in an msh3D background to eliminate any repair
mediated by the partially redundant Msh2-Msh3 heterodimer)
were MMR deficient at loci replicated in mid-S phase but were
proficient for MMR at loci replicated in late S phase or at mid-
S-phase loci moved to a late-S-phase replication site.10 These
previous findings together with the observation that CDC9-OE
interferes withMMR suggest that the lifetime of replication-asso-
ciated nicks control the temporal window for MMR. To test this,
we fused the G2/M tag to CDC9 to generate a strain in which
CDC9 expression was restricted to G2/M so that replication-
associated nicks persist throughout S phase (Figure 4A). Consis-
tent with a recent report,37 strains carrying theG2/M-CDC9 allele





Figure 3. Increased mutagenesis caused by Cdc9 overexpression is not due to the premature unloading of PCNA from DNA
(A) PCNA levels in whole cell extracts (WCE) and chromatin fractions. Histone H3 was the loading control. See also Figure S1D.
(B–D) In (B) and (D): mutation rate analysis using the lys2-10A frameshift reversion reporter in the indicated yeast genetic backgrounds. Bars correspond to the
median rate, with error bars indicating the 95% confidence interval. Numbers on top of the bars indicate fold increase in mutation rate relative to WT. See also
Table S2 for additional mutation rate analysis and Tables S3 and S4 for CAN1 mutation spectra analysis. (C) Correlation between Pms1-foci abundance and
frameshift mutator phenotype (hom3-10 assay). Quantification of Pms1-4GFP foci in boxplot with whiskers; dots represent outliers; black and red lines inside the
boxplot represent the median and the average, respectively. Statistical analysis indicated in (C) was performed relative to WT. p values shown in (B)–(D) were
calculated with the Mann-Whitney rank-sum test using SigmaPlot. **p % 0.01; ***p % 0.001; n.s., not significant.
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OPEN ACCESS Reportfragments relative to WT cells in S phase (Figure S2) but not in
G2/M phase when G2/M-Cdc9 is expressed (Figure 4A) or in
G1 phase. Moreover, strains expressing G2/M-Cdc9 exhibited
DNA-damage checkpoint activation and an accumulation of
cells in S phase (Figures S3A–S3C). In contrast, a strain carrying
the cdc9-FFAAmutant allele, which is expected to have reduced
ligase efficiency but normal expression timing, did not show
DNA-damage checkpoint activation or an accumulation of S-
phase cells (Figures S3A–S3C) and had less pronounced and
slightly larger Okazaki fragments than G2/M-CDC9 when cells
were arrested in S or G2/M phase (Figure S2).
The G2/M-CDC9 allele did not suppress the MMR defect of
the G2/M-MSH6 msh3D mutant strain measured at three mid-1272 Current Biology 31, 1268–1276, March 22, 2021S phase-replicated loci (Table S5), which is consistent with the
idea that mispair recognition must occur during DNA replica-
tion.10 We therefore constructed the G2/M-PMS1 allele to
restrict MMR steps after mispair recognition to the G2/M phase
of the cell cycle (Figure 4A). TheG2/M-PMS1 allele caused amu-
tator phenotype that was exacerbated by an exo1D mutation at
threemid-S phase-replicated loci (replication time, 32–39min af-
ter release from a-factor arrest)38 (Figure 4B; Table S5). In
contrast, the G2/M-PMS1 allele was 4 times more proficient at
suppressing mutations when the lys2-10A reporter was moved
to a late-replicated region (lys2-10ALATE),
10 which is replicated
49 min after release from a-factor arrest38 (Figure 4B) and coin-
cides with the time when G2/M-Pms1 reaches the peak level in
A
B
Figure 4. Cdc9 activity dictates a window of
time for MMR strand discrimination
(A) Top: Pms1 and Cdc9 protein expression levels
throughout the cell cycle under endogenous
regulation (PMS1-6HA andCDC9-9MYC) or under
control of the G2/M-tag (G2/M-PMS1-6HA and
G2/M-CDC9-9MYC). Bottom: logarithmically
growing cells (log), a-factor-arrested cells (a-F), or
cells arrested and released from a-F arrest for the
indicated time were analyzed by western blotting
and DNA content analysis. Sic1, Clb2, and tubulin
serve as G1-, G2/M-phase, and loading controls,
respectively. See also Figures S2 and S3.
(B) Mutation rate analysis using the lys2-10A
frameshift reversion assay in the indicated strains.
Bars correspond to the median rate, with error
bars representing the 95% confidence interval.
Numbers on top of the bars indicate fold increase
in mutation rate relative to the WT. p values were
calculated with the Mann-Whitney rank-sum test
using SigmaPlot. ***p % 0.001; n.s., not signifi-
cant. See also Table S5 for additional mutation
rate analysis using two alternative mutational
reporters.
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discrimination signal, the G2/M-PMS1mutator phenotype could
be due to the temporal uncoupling of this signal and the repair
machinery. Thus, we reasoned that mutations that cause the
signal to persist should suppress the G2/M-PMS1 mutator
phenotype. Remarkably, when the G2/M-PMS1 or the G2/M-
PMS1 exo1D alleles were combined with the G2/M-CDC9 or
the cdc9-FFAA allele, the mutator phenotype was largely sup-
pressed (Figure 4B; Table S5), with G2/M-CDC9 resulting in
stronger suppression. This observation is in agreement with
the more pronounced and slightly shorter Okazaki fragments
(indicative of a stronger Cdc9 ligase defect) in the G2/M-CDC9
strain arrested in S phase, compared to the cdc9-FFAA strain ar-
rested in either S or G2/M phase (Figure S2B). It should be noted
that the peak of G2/M-Cdc9 protein expression occurs 20 min
after the peak of G2/M-Pms1 protein expression, which could
explain why G2/M-Cdc9 protein expression does not inhibit
MMR in the G2/M-PMS1 strain. Furthermore, deletion of ELG1,Current Biowhich increases the amount of chro-
matin-associated PCNA (Figure S1D),35
resulted in a modest rescue of the muta-
tor phenotype of G2/M-PMS1 exo1D
(Figure 4B; Table S5). The suppression
of the G2/M-PMS1 exo1D mutator
phenotype by the previous mutations is
unlikely to be related to changes in cell-
cycle progression or activation of the
DNA damage response, as log-phase
cultures of the G2/M-PMS1 exo1D
elg1D and the G2/M-PMS1 G2/M-CDC9
exo1D triple mutants had relatively
normal DNAcontent profiles (Figure S3C).
These results, together with the observa-
tion that the cdc9-FFAA allele (which af-
fects neither cell-cycle progression norDNA damage response) also suppressed the G2/M-PMS1
exo1D strain mutator phenotype, indicate that the suppressive
effects of the G2/M-CDC9 and cdc9-FFAA alleles are a conse-
quence of the inefficient ligation of DNA replication-associated
nicks. Thus, by delaying the ligation of DNA replication-associ-
ated nicks, it is possible to retain MMR proficiency up to G2/M
phase for loci replicated in mid-S phase.
In conclusion, our findings indicate that MMR is sensitive to
the timing of DNA ligation and the lifetime of replication-associ-
ated nicks in DNA. Increased ligase activity causes a mutator
phenotype, whereas reduced or delayed ligase activity prolongs
the temporal window in which loci can undergo MMR. Impor-
tantly, these effects onMMRdid not correlate with the bulk levels
of chromatin-bound PCNA and were unaffected by loss of ribo-
nucleotide excision. Thus, these results suggest that replication-
associated nicks are the in vivo strand-discrimination signals in
eukaryotes, consistent with the requirement of pre-existing nicks
in reconstituted MMR reactions in vitro.5–8logy 31, 1268–1276, March 22, 2021 1273
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present on both the leading and lagging strands. The presence of
these nicks has been recently demonstrated by the high-
throughput mapping of DNA strand discontinuities on the
S. cerevisiae genome.11 Lagging-strand nicks are transient and
accumulate only when Okazaki fragment ligation is inhibited,
whereas leading-strand nicks are present at higher steady-state
levels than lagging-strand nicks in WT cells. The data currently
available are not sufficient to determine the absolute numbers
of leading- and lagging-strand nicks, as normalization controls
required when comparing different DNA libraries were not
included11 (H. Ulrich, personal communication). The minimum
density of nicks that is required to promote MMR in vivo is also
not currently known. However, the results of the studies pre-
sented here are consistent with the hypothesis that the nicks
present on the leading and lagging strands are sufficient to direct
strand specificity during MMR. In addition, the length of mitotic
gene conversion tracks in yeast, which are mediated by the for-
mation of heteroduplex DNA and subsequent MMR and range
from 7.3 to 32.3 kb in length,39,40 supports the idea that
MMR can catalyze mispair excision tracts that approach the
average distance between replication origins (20–40 kb) in
S. cerevisiae41 and, hence, even the low density of leading-
strand nicks significantly contribute toMMR. In addition, interac-
tions between MMR and the leading- and lagging-strand
replication machinery may also contribute to direct the strand
specificity of MMR.10,28
The absolute requirement of a pre-existing nick in MMR
reactions reconstituted in vitro may explain the fact that
Mlh1-Pms1 endonuclease activity is dispensable for many
MMR reactions reconstituted in vitro, although it is required
for MMR in vivo.30,42 In the context of DNA replication-
associated nicks acting as MMR strand-discrimination
signals, it can be anticipated that DNA ligase I activity would
suppress MMR. This idea is supported by our own results
and by the observation that reconstituted MMR reactions
using E. coli proteins were inhibited by the presence of DNA
ligase I, unless E. coli exonuclease I was added to the reac-
tion,43 which, in E. coli, appears to excise only a small number
of nucleotides (<50 nt) from the nick introduced by the MutH
endonuclease.44 Given the requirement for pre-existing nicks
to support MMR, it is unclear what role the eukaryotic Mlh1-
Pms1/PMS2 endonuclease plays in MMR in vivo. Based on
our findings, a possible role for the eukaryotic Mlh1-Pms1/
PMS2 endonuclease (with some marginal contribution of
Exo1) is to preserve DNA strand discontinuities on the newly
replicated strands to direct MMR. The Mlh1-Pms1/PMS2
endonuclease might accomplish this function by introducing
additional daughter-strand-specific nicks in the proximity of
the mispair site to convert ligatable nicks into non-ligatable
gaps to prevent the premature ligation of the strand disconti-
nuity before MMR is accomplished.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Antibodies
Mouse monoclonal anti-MYC (clone 4A6) Millipore Cat# 05-724; RRID: AB_11211891
Rat monoclonal anti-HA (clone 3F10) Roche Cat# 3F10; RRID: AB_2314622
Rabbit polyclonal anti-Clb2 Santa Cruz Cat# sc-9071; RRID: AB_667962
Mouse monoclonal anti-PCNA Abcam Cat# ab70472; RRID: AB_2160644
Rabbit polyclonal anti-Rnr3 Agrisera Cat# AS09 574; RRID: AB_1966947
Rat monoclonal anti-Tubulin & Rnr4 (clone YL1/2) Millipore Cat# MAB1864; RRID: AB_2210391
Mouse monoclonal anti-Histone H3 Abcam Cat# ab46765; RRID: AB_880439
Guinea pig polyclonal anti-Sic1 45 N/A




Zymolyase-100T US Biological Z1005
Restriction endonucleases (Bgl II, BamH I, Xho I, Not I, Sal I,
EcoR V, Kpn I)
New England Biolabs N/A
Sytox Green Thermo Fisher S7020
Hybond N+ membrane Amersham GE Healthcare RPN303B
3-Indoleacetic acid (Auxin) Sigma Aldrich I2886
Critical commercial assays
Megaprime DNA labeling system Amersham GE Healthcare RPN1606
PureGene Yeast/Bact. kit QIAGEN 158567
Experimental models: organisms/strains
MATa ura3-52 leu2D1 trp1D63 his3D200 hom3-10 lys2-10A 26 RDKY3686
MATa ura3-52 leu2D1 trp1D63 his3D200 hom3-10 lys2-10A 28 RDKY5964
RDKY5964 msh2::HIS3 46 HHY6505
RDKY5964 elg1::HIS3 this study HHY8074
RDKY5964 elg1::HIS3 exo1::hphNT1 this study HHY6828
RDKY5964 exo1::hphNT1 46 HHY1794
RDKY5964 exo1::hphNT1 LEU2.pol30-K217E this study HHY6035
RDKY5964 exo1-F447A-F448A-D571-702.kanMX4 this study HHY7017
RDKY5964 exo1-F447A-F448A-D571-702.kanMX4 natNT2.pGPD-CDC9 this study HHY7010
RDKY5964 natNT2.pGPD-CDC9 this study HHY6770
RDKY5964 natNT2.pGPD-CDC9-9MYC.HIS3 this study HHY8138
RDKY5964 natNT2.pGPD-CDC9 exo1::hphNT1 this study HHY6772
RDKY5964 natNT2.pGPD-CDC9 msh2::HIS3 this study HHY6899
RDKY5964 kanMX4.pGPD-CDC9 rad27::hphNT1 this study HHY7094
RDKY5964 natNT2.pGPD-ELG1 this study HHY8075
RDKY5964 natNT2.pGPD-ELG1 exo1::hphNT1 this study HHY6837
RDKY5964 pol2-M644G.natNT2 46 HHY1993
RDKY5964 kanMX4.pGPD-CDC9 natNT2.pGPD-ELG1 this study HHY6834
RDKY5964 kanMX4.pGPD-CDC9 exo1::hphNT1 natNT2.pGPD-ELG1 this study HHY6831
RDKY5964 kanMX4.pGPD-CDC9 elg1::HIS3 this study HHY6913
RDKY5964 kanMX4.pGPD-CDC9 exo1::hphNT1 elg1::HIS3 this study HHY6825
RDKY5964 LEU2.pol30-C81R this study HHY3234
(Continued on next page)
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Continued
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RDKY5964 LEU2.pol30-K217E this study HHY7555
RDKY5964 lys2::kl-TRP1 this study HHY7586
RDKY5964 natNT2.pGPD-CDC9 LEU2.pol30-K217E this study HHY7362
RDKY5964 pms1-A99V this study HHY5554
RDKY5964 rad27::hphNT1 this study HHY5082




RDKY5964 natNT2.pClb2-Clb2(1-181, L26A)-3MYC-CDC9 this study HHY6701
RDKY5964 natNT2.pClb2-Clb2(1-181, L26A)-MSH6 msh3::HIS3
natNT2.pClb2-Clb2(1-181, L26A)-3MYC-CDC9
this study HHY4983

































RDKY5964 leu2::ADH-AFB2.hphNT1 CDC9-9MYC-AID*.natNT2 this study HHY8076
RDKY5964 PMS1-4GFP.kanMX6 28 RDKY7588
RDKY5964 exo1::hphNT1 PMS1-4GFP.kanMX6 28 RDKY7544
RDKY5964 elg1::HIS3 PMS1-4GFP.kanMX6 this study HHY8077
RDKY5964 elg1::HIS3 exo1::hphNT1 PMS1-4GFP.kanMX6 this study HHY6982
RDKY5964 natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6 this study HHY8078
RDKY5964 exo1::hphNT1 natNT2.pGPD-CDC9 PMS1-
4GFP.kanMX6
this study HHY6895
RDKY5964 elg1::HIS3 natNT2.pGPD-CDC9 PMS1-4GFP.kanMX6 this study HHY6987
RDKY5964 elg1::HIS3 exo1::hphNT1 natNT2.pGPD-CDC9
PMS1-4GFP.kanMX6
this study HHY6978
RDKY5964 natNT2.pGPD-ELG1 PMS1-4GFP.kanMX6 this study HHY7499
RDKY5964 exo1::hphNT1 natNT2.pGPD-ELG1 PMS1-
4GFP.kanMX6
this study HHY7505
RDKY5964 kanMX4.pGPD-CDC9 natNT2.pGPD-ELG1 PMS1-
4GFP.kanMX6
this study HHY7142
RDKY5964 exo1::hphNT1 kanMX4.pGPD-CDC9 natNT2.pGPD-
ELG1 PMS1-4GFP.kanMX6
this study HHY7132
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Recombinant DNA
URA3 integrative plasmid (pop-in/pop-out) AmpR 47 pRS306
ori 2m URA3 AmpR 48 pRS426
pCH1572-pol30-C81R-LEU2 (one-step integrative plasmid) AmpR 49 pRDK926
kanMX4 AmpR 50 pFA6a-kanMX4
hphNT1 AmpR 50 pFA6a-hphNT1
natNT2 AmpR 50 pFA6a-natNT2
pGPD kanMX4 AmpR 50 pYM-N14
pGPD natNT2 AmpR 50 pYM-N15
C-terminal 3xMYC HIS3MX6 AmpR 50 pYM5
C-terminal 6xHA hphNT1 AmpR 50 pYM16
pCH1572-pol30-K217E-LEU2 (one-step integrative plasmid) AmpR This study pHHB252
pRS426-CDC9 2m URA3 AmpR This study pHHB1152
pRS426-cdc9-F44A-F45A 2m URA3 AmpR This study pHHB1163
pRS426-cdc9-K419A 2m URA3 AmpR This study pHHB1164
pRS426-cdc9-K598A 2m URA3AmpR This study pHHB1165
pRS306-cdc9-F44A-F45A URA3 integrative AmpR This study pHHB1274
pRS306-exo1-F447A-F448A URA3 integrative AmpR This study pHHB1187
pSM409-Nat-AID*-9MYC AmpR 24 pNat-AID*-9MYC
pFA6a-hphNT1-pADH-AFB2 AmpR This study pHHB699
pCLB2-3xMYC-(GA)5-CLB2(1-181+L26A).kanMX4 Amp
R This study pHHB1220
pCLB2-3xMYC-(GA)5-CLB2(1-181+L26A).hphNT1 Amp
R This study pHHB1221
pCLB2-3xMYC-(GA)5-CLB2(1-181+L26A).natNT2 Amp
R This study pHHB1222
pRS426-CDC9-HA 2m URA3 AmpR This study pHHB1194
pRS426-cdc9-F44A-F45A-HA 2m URA3 AmpR This study pHHB1195
pRS426-cdc9-K419A-HA 2m URA3 AmpR This study pHHB1196
pRS426-cdc9-K598A-HA 2m URA3 AmpR This study pHHB1197
Software and algorithms
SoftWoRx 6.1.1 Release 5 Applied Precision N/A
SigmaPlot version 10 Systat Software N/A
ImageJ, FIJI ImageJ https://fiji.sc




Information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hans Hombauer
(h.hombauer@zmbh.uni-heidelberg.de).
Materials availability
Plasmids and yeast strains generated in this study can be obtained through the Lead Contact.
Data and code availability
The published article includes all datasets generated or analyzed during this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Yeast strains
All S. cerevisiae strains used in this study are listed in the Key resources table and were derivatives of the S288C strains RDKY368626
(MATa ura3-52 leu2D1 trp1D63 his3D200 hom3-10 lys2-10A) or RDKY596428 (MATa version of RDKY3686). Strains were grown at
30C in yeast extract-peptone-dextrose media (YPD) or dextrose synthetic dropout media. Arginine dropout media containingCurrent Biology 31, 1268–1276.e1–e6, March 22, 2021 e3
ll
OPEN ACCESS Report60 mg/L of canavanine was used for selecting canavanine resistant cells (CanR). Gene deletions, gene tagging, and promoter re-
placements were done using standard PCR-based recombination methods,50 followed by confirmation by PCR and sequencing.
Strains containing two or more genetic modifications were usually obtained by mating and sporulation. All experiments were per-
formed with at least two independent biological isolates. With exception of the pol30-C81R and pol30-K217E alleles described
below, point mutations were introduced at their chromosomal loci with URA3-integrative vectors using pop-in/pop-out strategies,
and were confirmed by sequencing. Strains containing the lys2-10ALATE frameshift reporter (replicated during late S phase) were pre-
viously described.10
The pol30-C81R and pol30-K217E alleles were introduced at the POL30 locus by a one-step replacement after transformation with
Sac I-digested LEU2 plasmids pRDK92649 or pHHB252, respectively.
The cdc9-FFAAmutant allele that contains two consecutive phenylalanine-alanine substitutions (F44A and F45A) was introduced
at the CDC9 chromosomal locus using pop-in/pop-out strategy with the integrative plasmid pHHB1274 linearized with Bgl II.
Strains containing the pms1-A99V mutation were obtained after mating with RDKY417726 (MATa ura3-52 leu2D1 trp1D63 hom3-
10 lys2-10A exo1::URA3 pms1-A99V) and sporulation.
The strain expressing the exo1-F447A-F448A-D571-702 allele (referred in the main text as exo1-FFAA-D571-702) was generated
in two steps: (1) the exo1-F447A-F448A point mutations were introduced by pop-in/pop-out strategy with the pHHB1187 integrative
vector linearized with Bgl II; and (2) this strain was transformed with a PCR cassette carrying a kanMX4 module that introduces a
STOP codon in Exo1, right after codon 570.
The strain HHY8076, which expresses an auxin-inducible degron fused to the chromosomal copy of CDC9 (CDC9-9MYC-AID*-
natNT2) used for cdc9 plasmid complementation experiments (Figure S1A), was constructed by PCR-mediated recombination
with the plasmid pNat-AID*-9MYC.24 The strain HHY8076 also contains a pADH-AFB2.hphNT1 cassette (integrated at the LEU2
locus) that expresses the AFB2 F-box gene required for auxin-induced protein degradation. Integration of this cassette was




Plasmids used in this study are listed in the Key resources table. The pHHB1220-1222 plasmids were used as template DNAs in PCR
reactions to amplify the G2/M-tag (pClb2-Clb2(1-181+L26A)) linked to a selectable marker cassette (kanMX4, hphNT1 and natNT2,
respectively). TheG2/M-tag present in these three plasmids is identical to that contained in pRDK159810 plasmid, with the exception
that these constructs contain a tripleMYC-tag and a (GA)5 linker after the Clb2 N terminus (1-181 aa + L26A). These new plasmids are
now compatible with S1 and S4 primer design.50
High copy number plasmids (URA3, 2m, AmpR) harboringWT-CDC9, cdc9-FFAA, cdc9-K419A and cdc9-K598Awere constructed
using the pRS42648 backbone, and correspond to pHHB1152, pHHB1163, pHHB1164 and pHHB1165, respectively. These CDC9/
cdc9 overexpression plasmids contain the full-length CDC9 gene (including 1 kb of the promoter sequence and 300 bp of the termi-
nator region) cloned into the BamH I and Xho I sites present in the pRS426 polylinker. Cdc9 mutant alleles were generated by site-
directed mutagenesis. In addition, we constructed another set of plasmids that were almost identical to pHHB1152, pHHB1163,
pHHB1164 and pHHB1165 except that they harbor the WT-CDC9, cdc9-FFAA, cdc9-K419A and cdc9-K598A alleles fused to an
HA-tag at the C terminus, and are named pHHB1194, pHHB1195, pHHB1196 and pHHB1197, respectively.
The pHHB252 plasmid used to integrate the pol30-K217E allele was constructed as follows. First, the plasmid pRDK92549 con-
taining the pol30-C22Y mutant allele was reverted back to WT-POL30 by site-directed mutagenesis resulting in pHHB247. Next,
the pol30-K217E mutation was introduced by site-directed mutagenesis resulting in pHHB252.
The pHHB1274 plasmid used to integrate the cdc9-FFAAmutation was constructed as follows. The 3.6 kb BamH I-Xho I fragment
from pHHB1163, which contains the cdc9-F44A-F45A allele, was subcloned into the BamH I-Xho I sites in pRS306,47 resulting in
pHHB1274.
The pHHB1187 plasmid used to integrate the exo1-F447A-F448A mutant allele was constructed as follows. First, the WT-EXO1
gene (including 500 bp of the promoter and 253 bp of the terminator) was amplified by PCR from a WT yeast strain (RDKY5964)28
and cloned into theHind III and Xho I sites in pRS426, resulting in pHHB245. Next, the exo1-F447A-F448Amutationswere introduced
in pHHB245 by site-directed mutagenesis resulting in pHHB1186. Last, the 2.9 kb Not I-Xho I fragment from pHHB1186 was subcl-
oned into the Not I-Sal I sites in pRS306, resulting in pHHB1187.
The pHHB699 plasmid harboring the pADH-AFB2.hphNT1 cassette (used in auxin-induced protein degradation experiments) was
constructed by subcloning the 2.5 kb Sal I fragment from pRS303-ADH-AFB2 into the Sal I site in pFA6a-hphNT1,50 resulting in
pHHB699. Further analysis of this plasmid revealed that the AFB2 gene is in the same orientation as the hphNT1 resistance gene.
Whole cell lysates and western blotting
S. cerevisiae whole cell lysates and western blotting analysis were performed as described.28 Antibodies including catalog number
and manufacturer used in this study were: MYC (4A6, Millipore), HA (3F10, Roche), Clb2 (sc-9071, Santa Cruz), PCNA (ab70472, Ab-
cam), Rnr3 (AS09574, Agrisera), tubulin-Rnr4 (YL1/2, Sigma), Histone H3 (ab46765, Abcam) and Sic1 (previously described45). Ine4 Current Biology 31, 1268–1276.e1–e6, March 22, 2021
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OPEN ACCESSReportorder to detect PCNA more efficiently with the anti-PCNA antibody (ab70472, Abcam), the membrane was incubated in a mild strip-
ping buffer (0.2 M glycine pH 2.2, 0.1% SDS, 1% Tween 20) prior to blocking.
Cell synchronization and release
S. cerevisiae cells were synchronized by G1-arrest using a 3-hour incubation in the presence of 10 mg/ml a-factor (GenScript). For
release from G1-arrest, cells were washed with water and resuspended in YPD medium containing 15 mg/ml nocodazole (Sigma-
Aldrich) to prevent cells from entering a second G1 and S phase.
DNA content analysis
Analysis of DNA content in yeast cells was done as previously described.10
Mutation rate analysis
The lys2-10A and hom3-10 frameshift reversion assays, and the CAN1 inactivation assay were used to quantify mutation rates using
fluctuation analysis as previously described.26 Statistical significance was evaluated by calculating 95% confidence intervals.
Live cell imaging Pms1 foci
Exponentially growing cells were washed, resuspended and placed on agar pads, covered with a coverslip and sealed with valap
(1:1:1mixture of Vaseline, lanolin and paraffin by weight). Cells were imaged at 30C using a DeltaVision RT (Applied Precision) based
on an inverted microscope (IX70, Olympus) with a camera (CoolSNAP HQ2, Photometrics) and a Plan-Apo 100x (1.4 NA) oil immer-
sion objective lens (Olympus). 20 Z stacks spaced 0.3 mm were deconvolved using SoftWoRx software and projected using the
maximum intensity projection.
Detection of Okazaki fragments at the LYS2 locus
Genomic DNA from logarithmic cells, synchronized in G1 phase or G1-synchronized and released for the indicated times, was iso-
lated using the PureGene kit (QIAGEN). Approximately, 63 108 cells were used for each time point. DNA was resuspended in 30 mL
TE buffer (10 mM Tris pH 7.5, 0.1 mM EDTA) and kept at 4C or used immediately for Southern blot analysis. Quality, purity and con-
centration of the DNAwere evaluated by gel electrophoresis. Then, equal amounts of purified genomic DNAwere treatedwith EcoR V
overnight at 37C, mixed with loading dye containing 1 M urea, heated at 86C for 5 min, then loaded in 1.2% agarose gels and
resolved under urea/heat denaturing conditions; both the gel and running buffer contained 1 M urea and electrophoresis was for
5 hours at 80 V. The gels were blotted to Hybond N+ membrane (Amersham GE Healthcare Life Science) by capillary blotting. Hy-
bridization with 20 ng of 32P-radiolabelled probe was done in 2xSSC, 7% SDS and shared salmon sperm DNA (0.2 mg/ml) at
58C. To prepare the radiolabeled probe, the pHHB762 plasmid that harbors the LYS2 genomic sequence (including 600 bp of
the promoter sequence and 160 bp of the 30 UTR) was digested with Kpn I and Xho I and the 1.2 kb fragment was purified and
labeled with a-32P-dCTP using the Megaprime DNA labeling system (Amersham GE Healthcare Life Science). The probe was
purified from unincorporated nucleotides using Illustra microspin G-50 columns (Amersham GE Healthcare Life Science). Before
hybridization the probe was denatured 5 min at 95C and placed on ice before adding to the hybridization buffer. Membranes
were exposed to a phospho-screen, and the radioactive signal was detected with a Phosphor Imaging module (Sapphire
Biomolecular Imager).
Whole-cell extracts and chromatin fractions
Whole-cell extracts (WCEs) and chromatin enriched-fractions were prepared essentially as described previously.51 Approximately
3 3 108 logarithmically growing cells were harvested and resuspended in 1 mL of prespheroplasting buffer (100 mM PIPES/KOH,
pH 9.4, 10 mMDTT, 0.1% sodium azide) then incubated for 10 min on ice. Cells were then incubated in 1 mL of spheroplasting buffer
(50 mMKH2PO4/K2HPO4, pH 7.4, 0.8 M sorbitol, 10 mMDTT, 0.1% sodium azide) containing 200 mg/ml Zymolyase-100T at 30
C for
10 min with occasional mixing. Spheroplasts were washed twice with 1 mL of ice-cold wash buffer (20 mMKH2PO4/K2HPO4, pH 6.5,
0.8 M sorbitol, 1 mM MgCl2, 1 mM DTT, 20 mM b-glycerophosphate, 1 mM PMSF, protease inhibitor tablets (EDTA free, Roche)).
Spheroplasts were resuspended in 3 vol. of EB buffer (50 mM HEPES/KOH, pH 7.5, 100 mM KCl, 2.5 mM MgCl2, 0.1 mM ZnSO4,
2 mM NaF, 0.5 mM spermidine, 1 mM DTT, 20 mM b-glycerophosphate, 1 mM PMSF, protease inhibitor tablets (EDTA free)), lysed
by addition of Triton X-100 to 0.25%, and incubated on ice for 10min.WCEswere prepared bymixing 20 mL of the lysate with 20 mL of
23 Tris-Glycine SDS Sample Buffer and incubated for 3 min at 85C. The remaining lysate was laid over on 0.4 mL of EBX-S buffer
(EB buffer, 30% sucrose, 0.25% Triton X-100), and spun at 12,000 rpm for 10 min at 4C. The chromatin pellet was washed in 0.5 mL
of EBX buffer (EB buffer, 0.25%Triton X-100) and spun at 10,000 rpm for 2min at 4C. The chromatin pellet was resuspended in 50 mL
of 23 Tris-Glycine SDS Sample Buffer and incubated for 3 min at 85C. To detect PCNA, 10 mL of chromatin fractions were analyzed
in SDS-PAGE, followed by western blot with anti-PCNA antibody (ab70472, Abcam).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis for mutation rates as well as analysis of Pms1 foci were performed in SigmaPlot. P-values were calculated using
the Mann-Whitney rank sum test and were indicated on the graphs and represent statistical significance of the difference betweenCurrent Biology 31, 1268–1276.e1–e6, March 22, 2021 e5
ll
OPEN ACCESS Reportthe two data groups. Mutation rates analysis in S. cerevisiaewere determined using two independent biological isolates and a total of
at least 14 independent cultures. Themutation rate data shown in the graphs correspond tomedian rates for the indicatedmutational
reporter, the error bars correspond to the 95% confidence intervals. Quantification of Pms1 foci abundance was performed with at
least 1000 cells per genotype, using three independent biological isolates. Data presented in Figure 1B shows the average of the
percentage of cells containing foci, error bars indicate SEM. In Figure 3C data is presented as box-plots with whiskers and dots
represent outliers. Black and red lines inside the box represent the median and average of cells with foci, respectively.e6 Current Biology 31, 1268–1276.e1–e6, March 22, 2021
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Figure S1. Validation of the function of plasmid-borne CDC9 alleles and 
characterization of CDC9 overexpressing strains. Related to Figure 1, 2 and 3 and 
Table S2. 
(A) High copy number vectors were tested for their ability to complement a chromosomally 
encoded version of CDC9 fused to the auxin-inducible degron. Plasmids expressing WT 
CDC9 or cdc9-FFAA, which encodes a version of Cdc9 that cannot interact with PCNA in 
vitro, allowed cells to grow on YPD containing 4 mM auxin. In contrast, an empty vector 
(ev) control and both ligase-defective mutant alleles (cdc9-K419A and cdc9-K598A) could 
not. (B) Western blot analysis indicating expression levels of WT-Cdc9 or cdc9 mutant 
alleles (tagged with a C-terminal HA-tag) expressed from high copy number plasmids. An 
antibody against tubulin was used as a loading control. (C) Western blot analysis showing 
Cdc9 protein levels in yeast strains expressing the CDC9 gene at endogenous levels (endog. 
levels) or under the control of the strong constitutive promoter (pGPD), resulting in Cdc9-
overexpression (CDC9-OE). To facilitate the visualization of the Cdc9 protein, the 
chromosomal CDC9 gene was tagged at the C-terminus with a 9xMYC tag. (D) Abundance 
of PCNA in whole cell extracts (WCE) and chromatin-enriched fractions (chromatin) in the 
indicated mutant strains. Strains carrying the pol30-C81R and elg1Δ mutations, which were 
previously shown to have reduced or increased chromatin-bound PCNA levels, respectively 
[S1, S2], were included as controls. Inactivation of Elg1 results in an increase of Sumo-










Figure S2. CDC9 alleles with delayed (G2/M-CDC9) or reduced (cdc9-FFAA) ligase 
activity results in accumulation of unprocessed Okazaki fragments at the LYS2 locus. 
Related to Figure 4. 
(A) Diagram showing the strategy used for the generation of the P32-probe used for 
detection of Okazaki fragments at the LYS2 locus by Southern blotting. (B) Southern blot 
analysis used for the detection of Okazaki fragments at the LYS2 locus in WT and the 
G2/M-CDC9 or the cdc9-FFAA mutant strains either growing logarithmically (log), arrested 
in G1 phase by alpha-factor (α-F), synchronized in S phase (30 min release after α-F) or 
synchronized in G2/M phase (90 min release after α-F). A LYS2 deficient strain (lys2Δ) was 
used as a control for LYS2-P32 probe specificity. As a positive control, a plasmid harboring 
the LYS2 gene was digested with either EcoR V (detected as a 3.7 kb fragment) or Kpn I 




Figure S3. Delayed ligation of Okazaki fragments in the G2/M-CDC9 mutant results in 
activation of the DNA damage response and accumulation of cells in S phase. 
Related to Figure 4. 
(A, B) Whole cell lysates of the indicated strains were analyzed by western blotting with 
antibodies recognizing DNA damage-inducible ribonucleotide reductase subunits Rnr3 and 
Rnr4 [S4, S5]. A mutant strain expressing the pol2-M644G allele that results in activation of 
the DNA damage response [S6, S7] was included as a positive control. * denotes a cross-
reacting protein. Tubulin was used as a loading control. (C) DNA content analysis of the 
indicated logarithmically growing strains.  
 
 
 Mutation Rate (fold increase)* 
Relevant genotype Ura+ Lys+ Ura+ Thr+ Ura+ CanR 
wild-type + pRS426 1.1 [0.8-2.8] x 10-7 (1) 1.5 [0.8-2.6] x 10-8 (1) 7.7 [4.4-16.8] x 10-7 (1) 
wild-type + pRS426-CDC9 1.0 [0.5-1.8] x 10-6 (9) 6.8 [3.3-11.4] x 10-8 (4) 2.0 [1.5-2.5] x 10-6 (3) 
exo1Δ + pRS426 3.0 [1.3-6.1] x 10-7 (3) 1.6 [0.6-2.2] x 10-8 (1) 2.5 [2.2-3.2] x 10-6 (3) 
exo1Δ + pRS426-CDC9 1.0 [0.7-1.6] x 10-4 (940) 2.2 [1.8-3.1] x 10-6 (144) 9.4 [6.2-21.7] x 10-6 (12) 
exo1Δ + pRS426-cdc9-F44A-F45A 4.1 [2.2-8.1] x 10-6 (38) 6.4 [4.7-11.9] x 10-8 (4) 3.6 [2.8-4.4] x 10-6 (5) 
exo1Δ + pRS426-cdc9-K419A 2.7 [1.3-4.6] x 10-7 (2) 1.6 [1.3-2.6] x 10-8 (1) 2.5 [1.8-3.7] x 10-6 (3) 
exo1Δ + pRS426-cdc9-K598A 4.1 [2.6-9.5] x 10-7 (4) 1.8 [0.8-3.2] x 10-8 (1) 2.6 [1.9-3.4] x 10-6 (3) 
 
 
Table S1. Mutation rate analysis in strains overexpressing WT-CDC9 and cdc9 mutant 
alleles. Related to Figure 1A. 
* Median rates of lys2-10A (Ura+ Lys+) and hom3-10 (Ura+ Thr+) frameshift reversion and 
inactivation of CAN1 gene (Ura+ CanR) assays with 95% confidence interval in square 
brackets and fold increase relative to the wild-type in parentheses.  
 
 
 Mutation Rate (fold increase)* 
Relevant genotype Lys+ Thr+ CanR 
wild-type 1.5 [0.8-2.2] x 10-8 (1) 2.1 [1.4-3.2] x 10-9 (1) 7.2 [5.7-9.0] x 10-8 (1) 
msh2Δ 9.9 [8.1-10.8] x 10-5 (6771) 6.3 [5.2-12.8] x 10-6 (3053) 5.4 [4.4-7.2] x 10-6 (75) 
CDC9-OE 6.0 [4.6-6.9] x 10-8 (4) 5.4 [4.2-6.3] x 10-9 (3) 1.1 [0.8-1.4] x 10-7 (2) 
exo1Δ 9.8 [6.9-22.8] x 10-8 (7) 5.2 [3.3-7.9] x 10-9 (3) 4.3 [2.9-8.7] x 10-7 (6) 
CDC9-OE exo1Δ 6.1 [3.4-12.1] x 10-6 (416) 3.7 [2.8-5.7] x 10-7 (180) 1.3 [1.1-1.5] x 10-6 (18) 
exo1-FFAA-Δ571-702 3.6 [2.9-5.3] x 10-8 (2) 2.8 [2.0-4.7] x 10-9 (1) 8.2 [6.3-17.5] x 10-8 (1) 
CDC9-OE exo1-FFAA-Δ571-702 6.7 [4.4-10.8] x 10-6 (457) 3.4 [1.6-5.6] x 10-7 (163) 1.7 [0.7-2.8] x 10-6 (24) 
pol30-K217E 1.2 [0.8-2.4] x 10-6 (85) 4.1 [3.5-6.4] x 10-8 (20) 5.1 [3.9-10.7] x 10-7 (7) 
pol30-K217E  exo1Δ 5.5 [4.8-7.0] x 10-5 (3772) 2.7 [1.6-4.2] x 10-6 (1317) 7.1 [3.7-10.8] x 10-6 (99) 
CDC9-OE pol30-K217E   6.9 [6.1-9.5] x 10-6 (474) 2.1 [1.5-3.1] x 10-7 (103) 1.2 [1.0-1.3] x 10-6 (16) 
CDC9-OE exo1Δ pol30-K217E 3.0 [2.2-4.2] x 10-4 (20751) 2.1 [1.4-3.3] x 10-5 (10089) 2.0 [1.4-3.1] x 10-5 (278) 
pms1-A99V 4.0 [1.7-7.3] x 10-7 (27) 6.3 [4.0-9.7] x 10-8 (30) 4.0 [1.9-7.5] x 10-7 (6) 
CDC9-OE pms1-A99V  7.9 [3.4-12.4] x 10-6 (543) 1.4 [0.7-2.2] x 10-6 (688) 1.5 [1.1-1.7] x 10-6 (20) 
CDC9-OE msh2Δ 1.2 [0.6-2.0] x 10-4 (7948) 1.4 [0.9-2.1] x 10-5 (6533) 2.9 [1.1-3.7] x 10-5 (405) 
rnh201Δ 2.1 [1.7-3.3] x 10-8 (2) 5.5 [4.2-7.4] x 10-9 (3) 1.3 [0.8-1.9] x 10-7 (2) 
CDC9-OE rnh201Δ 9.6 [7.2-20.0] x 10-8 (7) 2.6 [1.9-3.2] x 10-8 (13) 6.0 [3.1-10.0] x 10-7 (8) 
exo1Δ rnh201Δ 2.0 [1.3-3.3] x 10-7 (14) 1.7 [1.2-3.1] x 10-8 (8) 8.0 [6.7-10.0] x 10-7 (11) 
CDC9-OE exo1Δ rnh201Δ 1.0 [0.5-2.0] x 10-5 (716) 1.2 [0.7-1.8] x 10-6 (561) 4.7 [1.8-6.6] x 10-6 (66) 
ELG1-OE 5.8 [4.2-8.2] x 10-7 (40) 8.5 [5.4-16.5] x 10-9 (4) 4.4 [3.4-6.0] x 10-7 (6) 
ELG1-OE exo1Δ  6.5 [4.9-8.5] x 10-7 (45) 4.7 [3.2-9.5] x 10-8 (23) 1.5 [1.0-2.0] x 10-6 (21) 
CDC9-OE ELG1-OE 5.6 [2.8-11.9] x 10-7 (38) 2.3 [1.4-3.2] x 10-8 (11) 5.6 [3.1-9.8] x 10-7 (8) 
CDC9-OE exo1Δ ELG1-OE  5.0 [2.8-7.3] x 10-5 (3387) 5.8 [3.5-9.1] x 10-6 (2809) 2.1 [1.5-3.6] x 10-5 (294) 
elg1Δ 1.0 [0.7-1.9] x 10-7 (7) 4.8 [3.4-10.2] x 10-9 (2) 1.8 [1.5-2.3] x 10-7 (3) 
CDC9-OE elg1Δ 2.3 [1.5-3.2] x 10-7 (16) 8.6 [5.8-11.1] x 10-9 (4) 3.4 [1.7-8.6] x 10-7 (6) 
exo1Δ elg1Δ 1.5 [0.7-2.2] x 10-7 (10) 1.7 [1.4-2.6] x 10-8 (8) 7.8 [6.0-12.3] x 10-7 (11) 
CDC9-OE exo1Δ elg1Δ 7.0 [4.2-11.7] x 10-7 (48) 7.4 [4.5-11.1] x 10-7 (355) 3.2 [1.9-4.4] x 10-6 (44) 
 
Table S2. Increased Cdc9 ligase activity interferes with Exo1-dependent and Exo1-
independent MMR. Related to Figure 2 and 3. 
* Median rates lys2-10A (Lys+) and hom3-10 (Thr+) frameshift reversion assays and 
inactivation of the CAN1 gene (CanR) with 95% confidence interval in square brackets and 
fold increase relative to the wild-type in parentheses.	  
 
 











CanR clones sequenced 92 119 101 92 97 164 
Mutations overall 92 (100.0) 119 (100.0) 101 (100.0) 92 (100.0) 98 (100.0) 169 (100.0) 
Base substitutions 69 (75.0) 87 (73.1) 77 (76.2) 25 (27.2) 20 (20.4) 62 (37.0) 
A-T → G-C 6 (6.5) 7 (5.9) 5 (5.0) 5 (5.4) 5 (5.1) 7 (4.1) 
G-C → A-T 18 (19.6) 31 (26.1) 28 (27.7) 7 (7.6) 11 (11.2) 30 (17.8) 
G-C → T-A 29 (31.5) 32 (26.9) 22 (21.8) 11 (12.0) 3 (3.1) 18 (10.7) 
A-T → C-G 3 (3.3) 3 (2.5) 5 (5.0) 1 (1.1) 0 (0.0) 4 (2.4) 
A-T → T-A 7 (7.6) 4 (3.4) 6 (5.9) 0 (0.0) 0 (0.0) 1 (0.6) 
C-G → G-C 6 (6.5) 10 (8.4) 11 (10.9) 1 (1.1) 1 (1.0) 2 (1.2) 
Transitions 24 (26.1) 38 (31.9) 33 (32.7) 12 (13.0) 16 (16.3) 37 (21.9) 
Transversions 45 (48.9) 49 (41.2) 44 (43.6) 13 (14.1) 4 (4.1) 25 (14.8) 
One-base-pair 
frameshifts 
15 (16.3) 11 (9.2) 15  (14.9) 58 (63.0) 78 (79.6) 106 (63.0) 
ΔA/T 5 (5.4) 2 (1.7) 7 (6.9) 34 (37.0) 56 (57.1) 75 (44.4) 
ΔG/C 3 (3.3) 6 (5.0) 5 (5.0) 3 (3.3) 18 (18.4) 15 (8.9) 
+A/T 6 (6.5) 3 (2.5) 2 (2.0) 21 (22.8) 4 (4.1) 13 (7.7) 
+G/C 1 (1.1) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 3 (1.8) 
Complex mutations† 8 (8.7) 21 (17.6) 9 (8.9) 9 (9.8) 0 (0.0) 1 (1.0) 
 
Table S3. CAN1 mutation spectra in CDC9-OE strains and exo1-mutants. Related to 
Figure 2. 
Mutation spectra analysis based on DNA sequencing of the CAN1 gene in independent CanR 
mutants, shown as the number of clones containing the indicated mutations, and in 
parenthesis as the percentage relative to the total. *CAN1 mutation spectrum of WT strain 
was taken from [S7]. ** CAN1 mutation spectrum of msh2Δ strain was taken from [S8].  
† includes multiple mutations within ten nucleotides, insertions or deletions of more than one 
































Table S4. Complex deletions and insertions found in the CDC9-OE strain  
(CAN1 mutation spectrum). Related to Figure 2. 
* mutation reported in the rad27Δ CAN1 mutation spectrum [S9]. ‡ the sequence of the 
upstream flanking repeat is GGTGCTGGGGT (11 nt) and the sequence of the downstream 
















    
 
1/119 16 bp 76-91 5 bp 
 
2/119 27 bp 284-310 8 bp 
 1/119 49 bp 762-810 11/12 bp‡ 
 1/119 15 bp 1134-1148 6 bp 
 1/119 63 bp 1286-1348 8 bp 
 1/119 16 bp 1324-1339 4 bp 
 1/119 39 bp 1625-1663 6 bp 
insertions 
9/119 (8%) 
    
 1/119 32 bp 225-256 6 bp 
 1/119 18 bp 290-307 4 bp 
 1/119 33 bp 399-431 4 bp 
 1/119 128 bp 688-815 none 
 1/119* 49 bp 762-810 11/12 bp‡ 
 1/119 72 bp 1265-1336 7 bp 
 1/119 50 bp 1384-1433 5 bp 
 1/119 38 bp 1580-1617 6 bp 
 







Table S5. MMR defect caused by the G2/M-PMS1 allele is largely suppressed by 
delaying Cdc9 expression or reducing Cdc9 ligase activity. Related to Figure 4. 
*Median rates of inactivation of the CAN1 gene (CanR) and lys2-10A (Lys+) and hom3-10 
(Thr+) frameshift reversion assays with 95% confidence interval in square brackets and fold 
increase relative to the wild-type in parentheses. # Mutation rates were taken from [S10]. 
 
 
 Mutation Rate (fold increase)* 
Relevant genotype Lys+ Thr+ CanR 
wild-type 1.5 [0.8-2.2] x 10-8 (1) 2.1 [1.4-3.2] x 10-9 (1) 7.2 [5.7-9.0] x 10-8 (1) 
G2/M-MSH6 msh3Δ# 2.9 [1.7-4.7] x 10-5 (1983) 4.3 [3.3-5.5] x 10-6 (2069) 2.9 [2.1-4.3] x 10-6 (40) 
G2/M-CDC9 8.0 [3.9-13.1] x 10-8 (5) 7.2 [4.8-10.0] x 10-9 (3) 4.0 [3.2-6.0] x 10-7 (6) 
G2/M-MSH6 msh3Δ G2/M-CDC9 2.7 [1.7-3.9] x 10-5 (1813) 2.8 [1.5-4.1] x 10-6 (1330) 3.5 [2.2-4.8] x 10-6 (49) 
G2/M-PMS1 6.1 [5.1-9.2] x 10-6 (418) 1.8 [1.3-2.4] x 10-7 (87) 5.9 [2.3-7.5] x 10-7 (8) 
G2/M-PMS1 G2/M-CDC9 1.1 [0.8-1.5] x 10-6 (76) 4.2 [1.7-5.6] x 10-8 (20) 5.7 [4.3-10.1] x 10-7 (8) 
G2/M-PMS1 cdc9-FFAA 2.8 [1.5-4.1] x 10-6 (194) 3.8 [2.7-6.5] x 10-8 (18) 2.1 [1.4-3.1] x 10-7 (3) 
G2/M-PMS1 exo1Δ 4.6 [3.3-5.8] x 10-5 (3118) 2.1 [1.4-3.1] x 10-6 (991) 2.7 [1.9-3.2] x 10-6 (38) 
G2/M-PMS1 lys2-10ALATE 1.5 [1.4-1.9] x 10-6 (105) 1.2 [1.0-1.4] x 10-7 (59) 2.3 [1.8-3.4] x 10-7 (3) 
G2/M-PMS1 exo1Δ G2/M-CDC9 2.3 [1.1-3.8] x 10-6 (157) 6.1 [4.4-8.0] x 10-8 (29) 1.4 [1.0-2.0] x 10-6 (20) 
cdc9-FFAA 1.2 [1.0-1.7] x 10-8 (1) 3.4 [1.6-5.3] x 10-9 (2) 8.5 [7.3-17.3] x 10-8 (1) 
G2/M-PMS1 exo1Δ cdc9-FFAA 7.8 [4.9-11.9] x 10-6 (536) 1.6 [0.9-2.4] x 10-7 (78) 1.1 [0.5-1.4] x 10-6 (15) 
G2/M-PMS1 exo1Δ elg1Δ 1.2 [0.9-1.4] x 10-5 (794) 5.2 [3.4-9.4] x 10-7 (249) 1.8 [1.3-2.8] x 10-6 (26) 
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